Archives
Antimycin A4: Advanced Inhibitor Profiling and Translatio...
Antimycin A4: Advanced Inhibitor Profiling and Translational Energy Metabolism Research
Introduction
Metabolic regulation in eukaryotic cells is orchestrated by a complex interplay of enzymatic pathways. For researchers dissecting these networks, Antimycin A4 (CAS 27220-59-3) offers a unique biochemical tool: it concurrently acts as an ATP-citrate lyase inhibitor and a mitochondrial respiratory chain inhibitor. This rare dual mechanism enables targeted interrogation of both cytosolic fatty acid/cholesterol biosynthesis and mitochondrial energy metabolism. While previous articles have examined Antimycin A4’s general research applications and mechanistic nuances, this article delivers a deeper analytical profiling—focusing on quantitative inhibition kinetics, structural determinants, and translational perspectives that bridge basic research and therapeutic innovation.
Structural Features and Biophysical Properties
Antimycin A4 is a bioactive natural product derived from Streptomyces species, characterized by a carboxyphenol amide core, a nine-membered cyclic bis-lactone, and distinct alkyl side chains. Its molecular formula is C25H34N2O9 (molecular weight: 506.55 Da). The compound is highly soluble in DMSO (Antimycin A4 DMSO soluble), making it suitable for in vitro and cell-based assays. For optimal stability, it should be stored at -20°C and solutions should be prepared fresh for each experiment.
Mechanism of Action: Dual-Pathway Inhibition
1. ATP-Citrate Lyase Inhibition
ATP-citrate lyase catalyzes the ATP-dependent cleavage of citrate into acetyl-CoA and oxaloacetate, supplying the cytosolic acetyl-CoA pool for fatty acid and cholesterol biosynthesis. Antimycin A4 competitively inhibits this enzyme by targeting the magnesium-citrate substrate-binding site. The inhibition constant (Ki) of 64.8 μM was determined using purified rat liver ATP-citrate lyase—an assay design described in the seminal study by Barrow et al. This competitive inhibition leads to measurable blockade of fatty acid and cholesterol metabolism, with translational implications for reducing serum triglycerides and LDL-cholesterol.
2. Mitochondrial Respiratory Chain Inhibition
Antimycin A4 also acts as a mitochondrial respiratory chain inhibitor, selectively targeting electron transport between cytochromes b and c1 within Complex III. This disrupts the mitochondrial electron transport chain, impeding the oxidative phosphorylation pathway and ATP synthesis. The resulting inhibition of eukaryotic energy metabolism is a powerful tool for probing mitochondrial function, studying apoptosis, and modeling metabolic stress in disease states.
Quantitative Profiling and Comparative Analysis
Inhibition Kinetics and Structure–Activity Relationships
According to Barrow et al. (1997), Antimycin A4 and related antimycins display a range of Ki values (4–60 μM), with A4’s Ki (64.8 μM) placing it at the upper end—indicating moderate-to-potent inhibition. Structural differences, such as side chain length and lactone ring conformation, directly influence both selectivity and potency for the metabolic enzyme targets. This structure–activity insight is crucial for researchers aiming to optimize inhibition profiles for specific experimental systems.
Comparison with Alternative Tools
While classic mitochondrial inhibitors (e.g., rotenone, oligomycin) and ACLY inhibitors (e.g., bempedoic acid) offer pathway-specific effects, Antimycin A4’s ability to concurrently block both the mitochondrial electron transport chain and cytosolic acetyl-CoA generation is distinctive. This duality allows for the dissection of compensatory metabolic fluxes—a capability not achievable with single-pathway inhibitors. Our focus on quantitative kinetics and dual-pathway blockade builds upon and extends beyond the mechanistic overviews found in recent articles such as "Antimycin A4: Bridging Mechanistic Insight and Translational Impact", which emphasize translational value but do not provide detailed kinetic or structural profiling.
Advanced Applications in Translational and Disease-Oriented Research
Metabolic Disease Modeling
Given its robust inhibition of fatty acid and cholesterol biosynthesis, Antimycin A4 serves as an invaluable energy metabolism research tool for modeling metabolic disorders. By suppressing acetyl-CoA production, it facilitates studies on hepatic steatosis, dyslipidemia, and atherosclerosis. Its capacity for serum triglyceride reduction and low-density lipoprotein cholesterol reduction in cellular systems positions it as a candidate molecule for preclinical metabolic screening platforms.
Cancer Metabolism Research
Aberrant mitochondrial function and lipid biosynthesis are hallmarks of many cancers. Antimycin A4 enables precise dissection of these metabolic pathways in tumor cell lines, supporting cancer metabolism research at the intersection of mitochondrial bioenergetics and lipid anabolism. Its dual inhibition profile allows researchers to evaluate metabolic plasticity, stress responses, and the efficacy of combinatorial metabolic therapies. This translational perspective extends beyond the systems biology focus in "Antimycin A4: Multifaceted Inhibitor for Metabolic Networks", by emphasizing disease-oriented assay design and application.
Functional Mitochondrial Studies
As a mitochondrial inhibitor tool compound, Antimycin A4 is instrumental in studies of mitochondrial membrane potential, reactive oxygen species (ROS) production, and apoptosis signaling. The ability to titrate inhibitory concentrations aligning with its Ki value allows for fine control of mitochondrial impairment, supporting investigations from fundamental bioenergetics to neurodegenerative disease models. Researchers can leverage its DMSO solubility for high-throughput cell-based assays or in vitro biochemical reconstitution.
Antibacterial and Commercial Fungicidal Activity
Originally isolated as an antibacterial antibiotic compound, Antimycin A4 retains activity against select Gram-positive bacteria and fungi. Its commercial fungicide applications stem from its disruption of eukaryotic respiratory chains, leading to growth inhibition in agricultural and laboratory contexts. The multi-pronged bioactivity of Antimycin A4 supports broad-spectrum utility in both basic and applied microbiology.
Practical Considerations for Experimental Design
- Solubility: Antimycin A4 is DMSO soluble; aqueous solutions are not recommended.
- Storage: Store powder at -20°C; avoid long-term storage of prepared solutions.
- Harvesting: Typical yields from in vitro fermentation reach ~3.5 μg/mL after 4 days.
- Dosing: Effective inhibitory concentrations should be matched to the Ki for the target pathway; titration is advised for cell-based and biochemical studies.
For detailed mechanistic protocols, the APExBIO Antimycin A4 (SKU C8711) datasheet provides validated assay conditions and handling instructions.
Content Hierarchy and Relationship to Existing Literature
This article provides a unique perspective by delivering a quantitative, structure–activity, and translationally focused analysis that complements prior reviews:
- While "Antimycin A4: Dual-Inhibition as a Translational Game-Changer" offers strategic guidance on clinical and preclinical applications, our analysis delves deeper into quantitative inhibition kinetics and structural determinants.
- Unlike "Antimycin A4: Dual-Pathway Inhibitor for Mitochondrial and Lipid Metabolism", which provides an overview of biochemical utility, this article emphasizes how dual inhibition enables advanced disease modeling and translational research, supported by a detailed comparison with alternative inhibitors.
- Building on the mechanistic foundation established in the original reference study, our article translates these findings into practical research strategies for modern metabolic and mitochondrial research.
Conclusion and Future Outlook
Antimycin A4 (APExBIO, CAS 27220-59-3) stands out as a premier research chemical for energy metabolism due to its dual role as an ATP-citrate lyase inhibitor and mitochondrial respiratory chain pathway blocker. Its structure–activity profile, quantitative inhibition data, and translational research applications position it as an indispensable tool for dissecting the intricacies of eukaryotic metabolism, modeling metabolic disorders, and exploring innovative therapeutic strategies. As metabolic research advances, future directions may include the synthesis of next-generation analogs with tailored selectivity or combinatorial use with other metabolic inhibitors. For researchers seeking robust, well-characterized inhibitors, Antimycin A4 from APExBIO represents a scientifically validated and operationally flexible choice for unraveling the complexities of cellular energy metabolism.